Neurology

The CDC reports an alarming level of pandemic-related psychological and behavioral distress including thoughts of suicide across US population segments.

In episode 1 of Primary Viewpoints, migraine specialist Peter McAllister, MD, discusses how the COVID-19 pandemic has impacted his migraine patients.

A survey of >15 000 UK respondents found people who have or had COVID-19 are more likely to develop general psychiatric disorders and loneliness.

How has the COVID-19 pandemic impacted migraine patients? We asked 3 migraine specialists that question and more.

Ketamine used in patients with treatment-resistant depression operates via serotonin 1B receptors by way of a previously unknown mechanism of action, according to a new study from Sweden.

Incident cardiovascular disease is significantly increased among women with migraine with aura vs migraineurs without aura and those who do not have migraine.

Analysis of data from more than 21 000 migraineurs found that less than 1 in 3 take prescribed acute medications and less than 1 in 5 take prescribed preventive agents.

As neurologic findings among patients with COVID-19 emerge, comparison to sequelae seen with other coronaviruses is instructive.

Over half of US adults who responded to a new survey said COVID-19 has impacted their mental health. To what extent? Find out in our new slideshow.

Almost half of Americans are anxious about contracting COVID-19, suggests a new American Psychiatric Association poll. More results at-a-glance here.

Frontline medical workers dealing with COVID-19 in China have a high risk of developing symptoms of depression, anxiety, insomnia, and distress.

Mental illness affects 1 in 5 US adults every year; some of them are your patients. This brief study of "the numbers" is essential.

Two first-in-class migraine drugs, the first generic version of NuvaRing®, and 7 more fourth quarter FDA-approved drugs for primary care.

A new study found a significant association between increased stroke risk and dual use of e-cigarettes and traditional cigarettes-authors urging physicians to use results as a wake-up call.

Highlights from a recent evidence-based review offer guidance on feasible depression treatments in primary care.

The FDA has approved the first oral CGRP receptor antagonist in pill form for the acute treatment of migraine with or without aura in adults.

ICYMI: Get a quick look at 12 of the many drugs FDA-approved in 2019 for conditions commonly seen in primary care.

When a patient presents to their primary care physician with a headache, it's not always diagnosed as the migraine it is. These 6 tips from a neurologist can help.

Highlights of an evidence-based review offer practical guidance for effective depression screening and assessment strategies for primary care physicians.

A new study being presented next week at AHA's 2019 Scientific Sessions found a strong link between depression and non-fatal heart disease. 

Two studies to be presented at the upcoming AHA annual meeting found that young cannabis users are at greater risk for stroke and arrhythmia. 

"Typical aura without headache" is a relatively rare headache diagnosis and not easy to make. Three leading headache specialists offer guidance on how to recognize and treat.

Lasmitidan is the first 5-HT1F receptor agonist to receive FDA approval and was found superior to placebo for reduction of migraine pain and most bothersome symptom at 2 hours.

Children, tweens, and adolescents with migraine can use Migraine Trainer to log and share details that will help physicians individualize care in this vulnerable population.

A new study suggests that deep brain stimulation may be a safe and effective treatment option for patients with treatment-resistant depression.